

DATA EXTRACTION TOOL

Participant Serial Number:

Pt: CTC ID (14digits) No.

ITEM	RESPONSE	ITEM	RESPONSE
A: Biodemographic data		C: Sample Timeline (dd/mm/yyyy)	
1. Age		14. Date of Test Request:	
2. Sex 0. Male 1. Female		15. Date of sample collection:	
3. Marital status 0. Single 1. Married		16. Date sample sent to lab	
4. Pregnancy 0. Pregnant 1. Not pregnant		17. Date sample received by lab	
5. TB infection 0. No 1. Yes		18. Sample type 0. DBS 1. Plasma 2. Blood	
6. Body weight (Kg)		C: ART exposure and HVL	
7. Height (m)		19. Date Verified HIV+: _____	
8. BMI (Kg/m ²)		20. Date ART started _____	
B: Address and Referring Centre		21. Date second line started. _____	
9. Ward:		22. Duration on 2 nd line _____ months	
10. District/Council:		23. Current 2nd line HAART REGIMEN	
11. Region:		_____, _____, _____	
12. Type of facility:		0. TDF + FTC + LPV/r 1. TDF + FTC + ATZ/r 2. ABC + 3TC + LPV/r 3. ABC + 3TC + ATV/r 4. AZT + 3TC + ATV/r 5. AZT + 3TC + LPV/r	
13. Cadre of Referring Coordinator 0. Nurse 1. Clinical Officer 2. Assistant Medical Officer 3. Medical Officer (MD) 4. Specialist			
		Other, Mention _____	

24. Previous ART regimen History

Regimen	Start date	Stop/change date	Duration on regimen (months)	Reason for change
1.				
2.				
3.				
4.				
5.				

Recent HIVL Results (with in past 6 months)

25. Pre EAC HIVL _____

Date sample taken _____

26. Pre EAC HIVL _____

Date sample taken _____

27. 26. Reported Adherence: _____

28. Current Adherence barriers: 0. Yes 1. Yes, If yes specify

Behavioral: _____

Cognitive: _____

Emotional: _____

Socioeconomical: _____

29. Comorbidities and opportunistic infections

Condition	ART regimen during treatment of condition	Medication/treatment for condition
1.		
2.		
3.		
4.		
5.		

D: Laboratory results from referring Centre

Laboratory Test	Result
30. CD4 Count	
31. Creatinine	
32. Creatinine Clearance CKD EPI	
33. ALAT	
34. ASAT	
35. CrAg	
36. Random Blood glucose	

E: Temeke Specialized laboratory

37. Date sample received: _____

38. Date sample tested: _____

39. Date results reported: _____

40. Date of Authentication: _____

PCR – Genotype results

41. HIV Viral Load	Copies/ml
42. HIV-1 Subtype	
43. PI Major Resistance Mutations	
44. PI Accessory Resistance Mutations	
45. NRTI Resistance Mutations	
46. NNRTI Resistance Mutations	

ART Susceptibility patterns

ART Drug	Susceptible	Low level Resistance	High level Resistance
<i>Protease Inhibitors (PI)</i>			
Atazanavir/r (ATV/r)			
Darunavir/r (DRV/r)			
Fosfamprenavir/r (FPV/r)			
Indinavir/r (IND/r)			
Lopinavir/r (LPV/r)			
Nelfinavir (NFV)			
Saquinavir/r (SQV/r)			
Tipranavir/r (TPV/r)			
<i>Nucleoside Reverse Transcriptase Inhibitors (NRTI)</i>			
Abacavir (ABC)			
Zidovudine (AZT)			
Stavudine (D4T)			
Didanosine (DDI)			
Emtricitabine (FTC)			
Lamivudine (3TC)			
Tenofovir (TDF)			
<i>Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)</i>			
Doravirine (DOR)			
Efavirenz (EFV)			
Etravirine (ETR)			
Nevirapine (NVP)			
Rilpivirine (RPV)			
<i>Extra parameters</i>			
PR Mutations			
RT Mutations			